This unit is active in disease prevention, mainly in the field of cardiovascular disease and epidemiological
transition (with a group active in the Seychelles since about 20 years), in close collaboration with the World
Health Organization (IUMSP as collaborating centre) and other international organizations.
Bovet P, Ross AG, Gervasoni JP, et al. Distribution of blood pressure, body mass index and smoking habits in the urban population of Dar es Salam, Tanzania, and associations with socio-economic status. Int J Epidemiol 2002;31:240-7.
Stettler N, Bovet P, Shamlaye H, et al. Prevalence and risk factors for overweight in children from Seychelles, a country in rapid transition: the importance of early growth. Int J Obesity 2002;26:214-9.
Lemogoum D, Seedat YK, Mabadeje AFB, et al. Recommendations for diagnosis and management of hypertension in sub-Saharan Africa. J Hypertens 2003;21:1993-2000.
Bochud M, Eap CB, Elston RC, et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006;24:923-9.
Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care setting ? a multinational comparison. Tob Control 2006;15(3):152-9.
Rodondi N, Humair JP, Ghali WA, et al. Counseling overweight and obese patients in primary care: a prospective study. Eur J Cardiovasc Prev Rehabil 2006;13:222-8.
The following files can be downloaded (right click on the filename):
|Panel-fr.pdf||Désaccoutumance au tabac en Suisse|
|Panel-de.pdf||Tabakentwöhnung in der Schweiz.|
|markovmodel.pdf||Markov Model for the Lausanne University Cost-effectiveness Analyses on Smoking Cessation Interventions|
|EUhosp_quest.pdf||Questionaire on smoking cessation conselling for inpatients in some european hospitals|
|EUhosp_data.pdf||Smoking cessation conselling availability in some european hospitals.|
|b_cas_res.xls||Table: Synthesis of cost-effectiveness ratios for a 45-year-old.|
|b_cas_res_age.xls||Table: Incremental cost-effectiveness ratios by age.|
|sa_trt_eff.xls||Table: Sensitivity Analysis - Treatment Efficacy.|
|sa_rel_1_Tx.xls||Table: Sensitivity Analysis - Relapse during 1st month of treatment.|
|sa_rel_2_Tx.xls||Table: Sensitivity Analysis - Relapse during 2nd month of treatment.|
|sa_prop_smo.xls||Table: Sensitivity Analysis - Proportion of smokers in "preparation" stage.|
|sa_nat_cess_rate.xls||Table: Sensitivity Analysis - Natural cessation rate.|
|sa_life_rel_rate.xls||Table: Sensitivity Analysis - Lifetime relapse rate.|
|patch_sa_Tx_price.xls||Figure: Sensitivity Analysis - Patch and Price.|
|patch_sa_Tx_eff.xls||Figure: Sensitivity Analysis - Patch and Efficacy.|
|patch_sa_GP_fees.xls||Figure: Sensitivity Analysis - Patch and GP fees.|